OK TO ENTER: /K.W/
`
`08/42/2015
`
`U.S. Application No.: 14/161,007
`Response after Notice of Allowancedated July 27, 2015
`Attorney Docket No.: 01-2051-US-3
`
`AMENDMENTSTO THE CLAIMS
`
`This listing of claims will replace all prior versions andlistings of claims in the
`
`application:
`
`Listing of Claims:
`
`Claims 1-14 (Cancelled).
`
`15.
`
`(Currently amended) A methodoftreating type 2 diabetes comprising
`
`methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a therapeutically
`
`active salt thereof,
`
`in an oral dosage of 2.5 mg or 5 mg, and (} metformin
`
`wherein the dose of metformin is 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a
`
`day), or 300 mg to 1000 mg once or twice a day, or as delayed-release metformin in a dose
`
`of 500 mg to 1000 mg onceortwice a day, or 500 mg to 2000 mg once a day,
`or
`
`wherein the dose of metformin is 500 mg, 850 mg or 1000 mg as a single dose with a total
`
`daily dose of metformin of 500-2850 mg, or 500 mg, 1000 mg, 1500 mg or 2000 mg
`
`metformin in delayed release form,
`or
`
`wherein the dose of metformin is 500 mg to 1000 mg.
`
`16.
`
`(Cancelled)
`
`17.
`
`(Previously presented) The method according to claim 15, wherein 1-[(4-methyl-
`
`quinazolin-2-yl)methy]]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-
`
`xanthine and metformin are administered orally in the form of a fixed combination.
`
`18.
`
`(Previously presented) The method according to claim 17, wherein the fixed
`
`combinationis a tablet or capsule.
`
`
`
`08/42/2015
`
`U.S. Application No.: 14/161,007
`Response after Notice of Allowancedated July 27, 2015
`Attorney Docket No.: 01-2051-US-3
`
`AMENDMENTSTO THE CLAIMS
`
`This listing of claims will replace all prior versions andlistings of claims in the
`
`application:
`
`Listing of Claims:
`
`Claims 1-14 (Cancelled).
`
`15.
`
`(Currently amended) A methodoftreating type 2 diabetes comprising
`
`methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a therapeutically
`
`active salt thereof,
`
`in an oral dosage of 2.5 mg or 5 mg, and (} metformin
`
`wherein the dose of metformin is 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a
`
`day), or 300 mg to 1000 mg once or twice a day, or as delayed-release metformin in a dose
`
`of 500 mg to 1000 mg onceortwice a day, or 500 mg to 2000 mg once a day,
`or
`
`wherein the dose of metformin is 500 mg, 850 mg or 1000 mg as a single dose with a total
`
`daily dose of metformin of 500-2850 mg, or 500 mg, 1000 mg, 1500 mg or 2000 mg
`
`metformin in delayed release form,
`or
`
`wherein the dose of metformin is 500 mg to 1000 mg.
`
`16.
`
`(Cancelled)
`
`17.
`
`(Previously presented) The method according to claim 15, wherein 1-[(4-methyl-
`
`quinazolin-2-yl)methy]]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-
`
`xanthine and metformin are administered orally in the form of a fixed combination.
`
`18.
`
`(Previously presented) The method according to claim 17, wherein the fixed
`
`combinationis a tablet or capsule.
`
`
`
`U.S. Application No.: 14/161,007
`Response after Notice of Allowancedated July 27, 2015
`Attorney Docket No.: 01-2051-US-3
`
`19.
`
`(Previously presented) The method according to claim 17, wherein the fixed
`
`combination is a tablet.
`
`Claims 20-23.
`
`(Cancelled)
`
`24.
`
`(Previously presented) The method according to claim 17, wherein the dosage of
`
`1-[(4-methy]-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn- 1-yl)-8-(3-(R)-amino-
`
`piperidin-1-yl)-xanthine is 2.5 mg.
`
`25.
`
`(Previously presented) The method according to claim 17, wherein the dosage of
`
`1-[(4-methy]-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn- 1-yl)-8-(3-(R)-amino-
`
`piperidin-1-yl)-xanthine is 5 mg.
`
`26.
`
`(Cancelled)
`
`27.
`
`(Previously presented) The method according to claim 17, wherein metformin is
`
`provided in a dose of 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a day), or 300 mg
`
`to 1000 mg once or twice a day, or as delayed-release metformin in a dose of 500 mg to
`
`1000 mg once or twice a day, or 500 mg to 2000 mg once a day.
`
`28.
`
`(Currently amended) The method according to claim 17, wherein the dose of
`
`metformin is 500 mg, 850 mg or 1000 mg as a single dose with a total daily dose of
`
`metformin of 500[[-]} sus
`
`to 2850 mg, or 500 mg, 1000 mg, 1500 mg or 2000 mg
`
`
`metformin in delayed release form.
`
`29.
`
`(Previously presented) The method according to claim 17, wherein the amountof
`
`metformin is 500 mg to 1000 mg.
`
`30.
`
`(Previously presented) The method according to claim 17, wherein the amountof
`
`metformin is 500 mg.
`
`
`
`U.S. Application No.: 14/161,007
`Response after Notice of Allowancedated July 27, 2015
`Attorney Docket No.: 01-2051-US-3
`
`31.
`
`(Previously presented) The method according to claim 17, wherein the amountof
`
`metformin is 850 mg.
`
`32.
`
`(Previously presented) The method according to claim 17, wherein the amountof
`
`metformin is 1000 mg.
`
`33.
`
`(Cancelled)
`
`34,
`
`(Cancelled)
`
`35.
`
`(Previously presented) A method oftreating type 2 diabetes comprising
`
`administering twice daily to a patient in need thereof 1-[(4-methyl-quinazolin-2-
`
`yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in an oral
`
`dosage of 2.5 mg in fixed combination with metformin in an amount of 500 mg to 1000
`
`mg.
`
`36.
`
`(Currently amended) An oral tablet formulation comprising 1-[(4-methyl-
`
`quinazolin-2-yl)methy]]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-
`
`xanthine in an amountof 2.5 mg or 5 mg optionally in combination with metformin, and
`
`[[an]] a pharmaceutically acceptable carrier or diluent.
`
`37.
`
`(Previously presented) The oral tablet according to claim 36, containing 500 mg to
`
`1000 mg metformin.
`
`38.
`
`(Currently amended) A methodoftreating type 2 diabetes comprising
`
`administering to a patient in need thereof {a} 1-[(4-methyl-quinazolin-2-yl)methyl]-3-
`
`methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a daily oral amountof
`
`5 mg and (3 metformin, i: the form of a fixed combination, wherein metforminis
`
`administered in a dose of 100 mg to 500 mg or 200 mg to 850 mg (1-3 timesa day), or 300
`
`mg to 1000 mg once or twice a day, or as delayed-release metformin in a dose of 500 mg
`
`to 1000 mg once or twice a day, or 500 mg to 2000 mg oncea day.
`
`
`
`U.S. Application No.: 14/161,007
`Response after Notice of Allowancedated July 27, 2015
`Attorney Docket No.: 01-2051-US-3
`
`39.
`
`(Currently amended) A methodoftreating type 2 diabetes comprising
`
`methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a daily oral amountof
`
`5 mg and (5) metformin, in the form of a fixed combination, wherein the dose of
`
`metformin is 500 mg, 850 mg or 1000 mg as a single dose with a total daily dose of
`
`metformin of 500-2850 mg, or 500 mg, 1000 mg, 1500 mg or 2000 mg metformin in
`
`delayed release form.
`
`40.
`
`(Currently amended) A methodoftreating type 2 diabetes comprising
`
`administering to a patient in need thereof {a} 1-[(4-methyl-quinazolin-2-yl)methyl]-3-
`
`methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a daily oral amountof
`
`5 mg and {}} metformin, in the form of a fixed combination, wherein the amountof
`
`metformin is 500 mg to 1000 mg.
`
`Al.
`
`(Previously presented) The method according to claim 15, wherein 1-[(4-methyl-
`
`quinazolin-2-yl)methy]]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-
`
`xanthine is administered in a daily oral amountof 5 mg.
`
`42.
`
`(Previously presented) A method oftreating type 2 diabetes comprising
`
`administering to a patient in need thereofthe oral tablet of claim 36, wherein the daily oral
`
`amount of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-
`
`amino-piperidin-1-yl)-xanthine administered to said patient is 5 mg.
`
`43.
`
`(Previously presented) The method according to claim 24, wherein 1-[(4-methyl-
`
`quinazolin-2-yl)methy]]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-
`
`xanthine in a dosage of 2.5 mg is administered twice daily.
`
`44.
`
`(Previously presented) The method according to claim 25, wherein 1-[(4-methyl-
`
`quinazolin-2-yl)methy]]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-
`
`xanthine in a dosage of Smg is administered once daily.
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
